Literature DB >> 9814493

Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone-releasing hormone receptor: Dwarfism of Sindh.

H G Maheshwari1, B L Silverman, J Dupuis, G Baumann.   

Abstract

We report, in detail, a new form of familial dwarfism, including its phenotypic features, hormonal profile, and molecular basis. Following a newspaper report of severe dwarfism in two villages in the province of Sindh, Pakistan, we organized an expedition to study its clinical, genetic, and molecular characteristics. We identified 18 dwarfs (15 male, 3 female), all members of a consanguineous kindred, ranging in age from newborn to 28 yr. Mean height was 7.2 SD below the norm, with mean adult heights of 130 cm for males and 113.5 cm for females. Body proportions and habitus were normal; but head circumference was 4.1 SD, and blood pressure approximately 3 SD below the norm. There was no dysmorphism, no microphallus, and no history of hypoglycemia. Serum GH did not respond to provocative stimuli (GHRH, L-dopa, or clonidine). Insulin-like growth factor I (IGF-I) and IGF-binding protein 3 were low (5.2 +/- 2.0 ng/mL and 0.42 +/- 0.13 microg/mL, respectively; mean +/- SD) but rose normally with GH treatment. One affected, dwarfed couple had a son, demonstrating fertility in both sexes. Clinical and endocrinological evidence suggested isolated GH deficiency with a recessive inheritance pattern. The GH-N gene was found to be intact. Linkage analysis of microsatellite chromosomal markers near other candidate genes yielded a high LOD score (6.26) for the GHRH receptor (GHRH-R) locus. DNA sequencing revealed a nonsense mutation (Glu50-->Stop) in the extracellular domain of the GHRH-R. This mutation predicts a severely truncated GHRH-R; it is identical to that recently reported in four patients from two other families. Inheritance is autosomal recessive (chromosome 7p) with a high degree of penetrance. Relatives heterozygous for the mutation had moderately decreased IGF-I levels and slightly blunted GH responses to GHRH and L-dopa, but they showed only minimal or no height deficit. This syndrome represents the human homologue of the little (lit/lit) mouse and closely resembles its phenotype. It demonstrates the absolute requirement of GHRH signaling for pituitary GH secretion and postnatal growth in humans, and its relatively minor (but discernible) biological importance in extrapituitary sites. The syndrome is distinct from other forms of GH deficiency with respect to microcephaly, asymptomatic hypotension, and absence of features such as facial dysplasia, significant truncal obesity, microphallus, or hypoglycemia. Its discovery raises the possibility of milder mutations in the GHRH-R gene as potential causes for partial GH insufficiency and idiopathic short stature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814493     DOI: 10.1210/jcem.83.11.5226

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Growth hormone and IGF-1.

Authors:  Roberto Salvatori
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

2.  GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome.

Authors:  R Salvatori; M G Serpa; G Parmigiani; A V O Britto; J L M Oliveira; C R P Oliveira; C M Prado; C T Farias; J C Almeida; T A R Vicente; M H Aguiar-Oliveira
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

3.  Short-term estradiol supplementation potentiates low-dose ghrelin action in the presence of GHRH or somatostatin in older women.

Authors:  Catalina Norman; Nanette Rollene; Suanne M Weist; Jean R Wigham; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

4.  Growth hormone (GH-1) gene deletions in children with isolated growth hormone deficiency (IGHD).

Authors:  Meena P Desai; Shilpa M Mithbawkar; Pradnya S Upadhye; Kavita K Shalia
Journal:  Indian J Pediatr       Date:  2011-10-21       Impact factor: 1.967

Review 5.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

6.  Molecular genetic studies in isolated growth hormone deficiency (IGHD).

Authors:  Meena P Desai; Shilpa M Mithbawkar; Pradnya S Upadhye; Sudha C Rao; Vijayalakshmi Bhatia; Madhava Vijaykumar
Journal:  Indian J Pediatr       Date:  2013-02-23       Impact factor: 1.967

7.  Transcript abundance in mouse pituitaries with altered growth hormone expression quantified by reverse transcriptase polymerase chain reaction implicates transcription factor Zn-16 in gene regulation in vivo.

Authors:  Patrick W Wojtkiewicz; Carol J Phelps; David L Hurley
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

8.  Older individuals heterozygous for a growth hormone-releasing hormone receptor gene mutation are shorter than normal subjects.

Authors:  Manuel H Aguiar-Oliveira; Marco A Cardoso-Filho; Rossana M C Pereira; Carla R P Oliveira; Anita H O Souza; Elenilde G Santos; Viviane C Campos; Eugênia H O Valença; Francielle T de Oliveira; Luiz A Oliveira-Neto; Miburge B Gois-Junior; Alecia A Oliveira-Santos; Roberto Salvatori
Journal:  J Hum Genet       Date:  2015-03-12       Impact factor: 3.172

9.  Unusual phenotypic features in a patient with a novel splice mutation in the GHRHR gene.

Authors:  Latifa Hilal; Yassir Hajaji; Marie-Pierre Vie-Luton; Zeina Ajaltouni; Bouchra Benazzouz; Maha Chana; Adelmajid Chraïbi; Abdelkrim Kadiri; Serge Amselem; Marie-Laure Sobrier
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

Review 10.  The GH/IGF-1 axis in ageing and longevity.

Authors:  Riia K Junnila; John J Kopchick; Edward O List; Darlene E Berryman; John W Murrey
Journal:  Nat Rev Endocrinol       Date:  2013-04-16       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.